<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neogenomics Inc — News on 6ix</title>
<link>https://6ix.com/company/neogenomics-inc</link>
<description>Latest news and press releases for Neogenomics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neogenomics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a16a78dffbe2df10948a.webp</url>
<title>Neogenomics Inc</title>
<link>https://6ix.com/company/neogenomics-inc</link>
</image>
<item>
<title>NeoGenomics Reports First Quarter 2026 Results</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-reports-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-reports-first-quarter-2026-results</guid>
<pubDate>Tue, 28 Apr 2026 20:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., April 28, 2026--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.</description>
</item>
<item>
<title>NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-expands-access-to-full-oncology-testing-portfolio-through-epic-aura-integration</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-expands-access-to-full-oncology-testing-portfolio-through-epic-aura-integration</guid>
<pubDate>Thu, 23 Apr 2026 04:00:00 GMT</pubDate>
<description>EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption FORT MYERS,</description>
</item>
<item>
<title>/C O R R E C T I O N -- Neo Performance Materials, Inc./</title>
<link>https://6ix.com/company/neogenomics-inc/news/c-o-r-r-e-c-t-i-o-n-neo-performance-materials-inc</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/c-o-r-r-e-c-t-i-o-n-neo-performance-materials-inc</guid>
<pubDate>Fri, 10 Apr 2026 11:00:00 GMT</pubDate>
<description>Neo Performance Materials Inc. ("Neo" or the "Company") (TSX: NEO) (OTCQX: NOPMF) today announced the successful commissioning of its heavy rare earth element ("HREE") solvent extraction small-scale production line at its Silmet facility in Estonia. The solvent extraction line is operating at nameplate capacity, with efforts now focused on delivering stable product purity prior to transitioning to routine production capacity.</description>
</item>
<item>
<title>NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-to-report-first-quarter-2026-financial-results-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-to-report-first-quarter-2026-financial-results-on-april-28-2026</guid>
<pubDate>Tue, 07 Apr 2026 11:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., April 07, 2026--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls a</description>
</item>
<item>
<title>Neo Performance Materials Reports Fourth Quarter 2025 Results</title>
<link>https://6ix.com/company/neogenomics-inc/news/neo-performance-materials-reports-fourth-quarter-2025-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neo-performance-materials-reports-fourth-quarter-2025-results-1</guid>
<pubDate>Thu, 19 Mar 2026 11:00:00 GMT</pubDate>
<description>Neo Performance Materials Inc. ("Neo" or the "Company") (TSX: NEO) (OTCQX: NOPMF) today announced its financial results for the fourth quarter and full year 2025. Neo's financial statements and management's discussion and analysis ("MD&A") for the year ended December 31, 2025, are available at neomaterials.com and on SEDAR+ at sedarplus.ca. All financial amounts in this news release and the Company's financial disclosures are in United States dollars, unless otherwise stated.</description>
</item>
<item>
<title>NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-pantracer-lbx-receives-medicare-coverage-expanding-access-to-comprehensive-liquid-biopsy-profiling</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-pantracer-lbx-receives-medicare-coverage-expanding-access-to-comprehensive-liquid-biopsy-profiling</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine,</description>
</item>
<item>
<title>NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-launches-radar-st-expanding-molecular-residual-disease-testing-across-multiple-solid-tumor-types</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-launches-radar-st-expanding-molecular-residual-disease-testing-across-multiple-solid-tumor-types</guid>
<pubDate>Wed, 25 Feb 2026 12:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., February 25, 2026--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.</description>
</item>
<item>
<title>NeoGenomics Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-reports-fourth-quarter-full-120500354</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-reports-fourth-quarter-full-120500354</guid>
<pubDate>Tue, 17 Feb 2026 12:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., February 17, 2026--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.</description>
</item>
<item>
<title>NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-introduces-pantracer-pro-support-120500657</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-introduces-pantracer-pro-support-120500657</guid>
<pubDate>Thu, 12 Feb 2026 12:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., February 12, 2026--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.</description>
</item>
<item>
<title>NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-report-fourth-quarter-full-120500415</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-report-fourth-quarter-full-120500415</guid>
<pubDate>Tue, 27 Jan 2026 12:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., January 27, 2026--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.</description>
</item>
<item>
<title>NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-announces-preliminary-fourth-quarter-120500440</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-announces-preliminary-fourth-quarter-120500440</guid>
<pubDate>Mon, 12 Jan 2026 12:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., January 12, 2026--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.</description>
</item>
<item>
<title>NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today</description>
</item>
<item>
<title>NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-appoints-diagnostics-lab-services-120500928</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-appoints-diagnostics-lab-services-120500928</guid>
<pubDate>Tue, 30 Dec 2025 12:05:00 GMT</pubDate>
<description>FORT MYERS, Fla., December 30, 2025--NeoGenomics announced the appointment of John P. "Jack" Kenny to its Board of Directors.</description>
</item>
<item>
<title>NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-appoints-diagnostics-and-lab-services-industry-veteran-john-p-jack-kenny</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-appoints-diagnostics-and-lab-services-industry-veteran-john-p-jack-kenny</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today</description>
</item>
<item>
<title>NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-announces-natera-has-voluntarily-withdrawn-its-appeal-ongoing-radar</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-announces-natera-has-voluntarily-withdrawn-its-appeal-ongoing-radar</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.--(BUSINESS WIRE)--</description>
</item>
<item>
<title>NeoGenomics to Present New ctDNA Research at SABCS 2025</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-present-new-ctdna-research-sabcs-2025-2025-12-10</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-present-new-ctdna-research-sabcs-2025-2025-12-10</guid>
<pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
<description>Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer FORT MYERS,</description>
</item>
<item>
<title>NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-present-real-world-study-comprehensive-genomic-profiling-myeloid</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-present-real-world-study-comprehensive-genomic-profiling-myeloid</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will</description>
</item>
<item>
<title>NeoGenomics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-participate-upcoming-investor-conferences-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-participate-upcoming-investor-conferences-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today</description>
</item>
<item>
<title>NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-present-radar-st-bridging-study-islb-2025-demonstrating-reliable-mrd</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-present-radar-st-bridging-study-islb-2025-demonstrating-reliable-mrd</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors FORT MYERS, Fla.--(BUSINESS WIRE)--</description>
</item>
<item>
<title>NeoGenomics Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/neogenomics-inc/news/neogenomics-reports-third-quarter-2025-results-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/neogenomics-inc/news/neogenomics-reports-third-quarter-2025-results-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24%</description>
</item>
</channel>
</rss>